OSR Holdings Signs $80 Million Stock Deal to Support Brain Cancer Research: Shares Up

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

OSR Holdings Signs $80 Million Stock Deal to Support Brain Cancer Research: Shares Up

, MT Newswires - 8:27 AM ET 4/3/2025 default

08:27 AM EDT, 04/03/2025 (MT Newswires) -- OSR Holdings ( OSRH ) said Thursday it signed an agreement allowing it to sell up to $80 million in stock to White Lion GBM Innovation Fund.

The capital will support OSR's global efforts to develop new therapies, including glioblastoma treatments, the company said.

The funding agreement gives OSR the option to sell shares gradually over time but does not obligate it to do so.

OSR's biotech portfolio includes Vaximm, a Swiss subsidiary developing an immunotherapy vaccine for glioblastoma.

Shares of the company were up more than 55% in recent Thursday premarket activity.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.